Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
United States | Publication | June 3, 2020
On May 4, 2020, the Chair and the Director of the Office of Municipal Securities of the US Securities and Exchange Commission (the Commission) issued a statement (the Statement1) urging municipal securities issuers to disclose as much information as practicable regarding the current and potential future impact of COVID-19 on their financial and operating conditions, regardless of whether they are then issuing securities in the primary market.2 Providing as much current and forward-looking issuer- and security-specific information as is practicable, they state, will benefit municipal securities issuers. That conclusion is certainly debatable, and it is our view that such issuers should consult with their advisors before acting on the recommendations in the Statement. We summarize the Statement below and also include caveats to the Statement's advice.
The Statement notes the complexity and diversity of the municipal securities market, its issuers and investors (about one million different debt securities outstanding issued by about 50,000 different issuers with a range of security structures and held predominately by retail3, buy-and-hold investors), factors that are largely absent from the corporate securities market. It fails to note that, unlike the overall corporate securities market, the municipal securities market is limited to debt securities, the trading value of which fluctuates much less than equity securities in reaction to changes in an issuer's financial performance. It is also predominately a market for investment grade debt securities where defaults, despite certain high-profile exceptions, are very rare. Nevertheless, the Statement claims that investors in both markets have an equal "need" for timely, accurate, consistent and fairly disseminated current and forward looking information regarding an issuer's financial and operating status. Whatever the "need" of investors, the Statement observes that it has grown in the face of the COVID-19 pandemic and its effect on state and local governments, many of which are in the front lines dealing daily with this once-in-a-hundred-years public health crisis4.
As a consequence, the Statement's authors "urge [municipal] issuers to consider providing voluntary disclosure regarding the current and reasonably anticipated future impacts of COVID-19 on their operational and financial condition," including in the following areas:
The complexity and diversity of the municipal securities market noted above makes a "one size fits all" approach to municipal disclosure difficult if not impossible to implement, despite the exhortations in the Statement. In addition, compiling and then distilling for investors information about an issuer's financial status and operating condition, when the issuer is simultaneously addressing an "all hands on deck" pandemic within its jurisdiction, might (if not will) necessitate diversion of finite resources from more important needs. Without acknowledging these realities, the authors of the Statement conclude that, in their opinion, these disclosures "will benefit issuers," and the scale tips in favor of making them because, among other things:
By including such "cautionary language" in any voluntary public disclosure, the Statement's authors, speaking only on their behalf, as noted in footnote 1 above, "would not expect good faith attempts to provide appropriately framed current and/or forward-looking information to be second guessed" by the Commission (presumably through an after-the-fact SEC enforcement action), although the Statement is not binding on it.
That said, absent an issuer being "in the market" offering its debt securities (including "rolling" commercial paper or possibly remarketing demand paper) or facing a Rule 15c2-12 contractual continuing disclosure undertaking filing deadline (either with respect to its annual financial and operational information update or the occurrence of one or more of the 16 listed events8), municipal issuers are not under a general obligation to update investors and the market regarding material changes in financial and operating condition. The Statement acknowledges this fact.
Despite the liability protections noted above and the Statement authors' opinions regarding Commission enforcement action being unlikely if such protections are availed of, not all liability under the federal securities laws can be cautioned away. Once an issuer voluntarily speaks publicly about its financial or operating affairs in a manner expected to reach investors (even if the issuer didn't intend that investors rely on this information and even if it is not "in the market" offering its securities), it is obligated not to misstate or misleadingly omit a material fact. In the absence of a voluntary public statement, the only obligation of an issuer that is not currently engaged in the primary market is complying with its contractual continuing disclosure undertaking.
That undertaking, required pursuant to the Commission's regulatory supervision (as set forth in the Rule) over broker-dealers, not municipal issuers, is not an obligation to supply current or forward-looking information (aside from currently notifying the market of the occurrence as to the particular issuer of any of the 16 listed events). It does not require an issuer to disclose more recent information or forecast future prospects regarding COVID-199. When historical information is provided in accordance with a continuing disclosure undertaking, an issuer could (i) note that the information is provided to comply with a contractual undertaking, (ii) explain how the COVID-19 pandemic has affected and may continue to affect the issuer’s financial and operating performance and (iii) caution that the historical information provided is, therefore, not indicative of future financial results. With such language accompanying an issuer’s annual information or listed event filing under the Rule, no investor can be misled by the omission of more recent quantitative information or forecasts from the filing. Disclosing the information urged by the Statement’s authors would, thus, not appear to be required to avoid a violation of the anti-fraud provisions of the federal securities laws.
The SEC's statutory purposes include the protection of investors and maintenance of fair capital markets. A municipal issuer has a different mission, one of protecting the health, safety and welfare of its residents, employees and customers, including taking all necessary (and at times unpopular) action to deal with COVID-1910. The Commission has the benefit of 20-20 hindsight in its enforcement actions that help carry out those (and its other) purposes. Municipal issuers do not have that benefit11. Even taking into account the potential benefit of improved investor relations, municipal issuers may reasonably determine that the burden and risks of providing voluntary disclosure outweigh the benefits. Accordingly, under the current circumstances of dealing with COVID-19 and the uncertainties of a rapidly changing information landscape, many issuers may appropriately decide not to make voluntary market disclosures of their current or projected financial condition, despite the Statement's urging to the contrary.
If you have further questions regarding the impact of the Statement on a particular issuer, or would like advice concerning possible voluntary COVID-19 current or forward-looking disclosure, please reach out to Lawrence Bauer, Fredric (Rick) Weber, Paul Braden or your customary Norton Rose Fulbright lawyer or lawyers.
Publication
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Publication
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023